[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365477-105":59,"doc-detail-365477-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rethinking-myc-inhibition-a-multi-dimensional-approach-to-overcome-cancers-master-regulator","Rethinking MYC inhibition - a multi-dimensional approach to overcome cancer’s master regulator","","MYC inhibition is reframed as clinically tractable despite MYC’s historically “undruggable” intrinsically disordered structure. The review synthesizes progress from direct inhibitors such as Omomyc (OMO-103) and PROTAC-based degraders like WBC100, alongside complementary indirect strategies including BET and CDK9 inhibitors, RNA-based therapeutics, nanobodies, and engineered proteases. It weighs ongoing concerns about specificity, toxicity, and delivery, then highlights biomarker-guided, multi-dimensional combination regimens with chemotherapy, radiotherapy, or immunotherapy to counter resistance and improve outcomes in MYC-driven cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rethinking-myc-inhibition-a-multi-dimensional-approach-to-overcome-cancers-master-regulator/365477/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rethinking-myc-inhibition-a-multi-dimensional-approach-to-overcome-cancers-master-regulator/365477.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why has MYC been considered “undruggable” historically?","Question",{"text":112,"@type":113},"MYC’s intrinsically disordered structure lacks defined binding sites for conventional small-molecule inhibitors, and concerns about toxicity in normal proliferating cells have limited clinical development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What direct and degradation-based approaches are highlighted for MYC inhibition?",{"text":117,"@type":113},"The text cites direct inhibition with Omomyc (OMO-103) and PROTAC-based degraders such as WBC100, emphasizing emerging clinical progress and feasibility.",{"name":119,"@type":110,"acceptedAnswer":120},"How do combination therapies support MYC-targeted treatment?",{"text":121,"@type":113},"Combining MYC inhibitors with chemotherapy, radiotherapy, or immunotherapy is described as potentially synergistic, and the review emphasizes biomarker-guided rational combinations to improve outcomes and address resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365477,1790383924,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Mini Review  \nPUBLISHED 29 April 2025  \nDOI 10.3389/fcell.2025.1601975  \nOPEN ACCESS  \nEDITED BY  \nSaleha Anwar,  \nJamia Hamdard University, India  \nREVIEWED BY  \nZhuoyao Chen,  \nUniversity of Oxford, United Kingdom  \n*CORRESPONDENCE  \nChunxia Sun,  \n [1042159109@qq.com](1042159109@qq.com)[ ](1042159109@qq.com)Zihan Su,  \n [315548956@qq.com](315548956@qq.com)  \n†These authors have contributed equally to this work  \nRECEIVED 28 March 2025  \nACCEPTED 21 April 2025  \nPUBLISHED 29 April 2025  \nCITATION  \nYu J, Liu D, Yuan Y, Sun C and Su Z (2025) Rethinking MYC inhibition: a  \nmulti-dimensional approach to overcome cancer’s master regulator.  \nFront. Cell Dev. Biol. 13:1601975 .  \ndoi: 10.3389/fcell.2025.1601975  \nCOPYRIGHT  \n© 2025 Yu, Liu, Yuan, Sun and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nRethinking MYC inhibition: a multi-dimensional approach to overcome cancer’s master regulator  \nJing Yu 1†, Dan Liu 1†, Yujian Yuan 2†, Chunxia Sun 1* and Zihan Su 1* 1Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao, Municipal Hospital, Qingdao, China, 2Qingdao Preschool Techers’ School, Qingdao, China  \nMYC, a master regulator in oncogenesis, has long been deemed “undruggable”due to its intrinsically disordered structure. However, recent advances are overturning this view, with direct inhibitors like Omomyc (OMO-103) and PROTAC-based degraders such as WBC100 showing promising clinical progress. Complementary strategies—including BET and CDK9 inhibitors, RNAbased therapeutics, nanobodies, and engineered proteases—are expanding the therapeutic landscape. Despite challenges in specificity, toxicity, and delivery, these innovations underscore MYC’s emerging druggability. Moreover, combination therapies integrating MYC inhibitors with chemotherapy, radiotherapy, or immunotherapy demonstrate synergistic potential. This article advocates for a multi-dimensional, biomarker-guided approach to MYC targeting, emphasizing rational drug combinations and continued innovation to overcome resistance and improve outcomes in MYC-driven cancers.  \nKEYWORDS  \nMYC inhibition, cancer therapy, direct MYC targeting, indirect MYC targeting, combination therapies  \n1 Introduction  \nThe MYC oncogene has been widely recognized as a master regulator implicated in numerous hallmarks of cancer, including uncontrolled proliferation, sustained tumor growth, metastasis, immune evasion, and therapy resistance (Papadimitropoulou et al., 2024; Whitfield and Soucek, 2025; Jha et al., 2023) . Despite being among the most attractive therapeutic targets in oncology, MYC has historically been labeled as “undruggable” due to its intrinsically disordered structure, lacking defined binding sites required for traditional small-molecule inhibitors (Llombart and Mansour, 2022; Jain et al., 2024) . This structural complexity, combined with concerns about the potential toxicity of MYC inhibition in normal proliferating cells, has significantly impeded the development of effective clinical therapies targeting MYC (Wu et al., 2023) .  \nMYC overexpression or dysregulation has been implicated in a broad spectrum of malignancies, including breast, and ovarian cancers, among others (ZacarأasFluck et al., 2024; Bi et al., 2024) . In breast cancer, MYC amplification is observed in approximately 15%–30% of cases, particularly in triple-negative breast cancer (TNBC) and HER2-positive subtypes, where it drives aggressive tumor behavior  \nFrontiers in Cell and Developmental Biology 01 [frontiersin.org](frontiersin.org)  \nand resistance to standard therapies (G","cbCaiuCcp1ss7Nr7","https://ap.wps.com/l/cbCaiuCcp1ss7Nr7","pdf",222264,"English","# Introduction\n# Challenging the Myth of undruggable MYC","[{\"question\":\"Why has MYC been considered “undruggable” historically?\",\"answer\":\"MYC’s intrinsically disordered structure lacks defined binding sites for conventional small-molecule inhibitors, and concerns about toxicity in normal proliferating cells have limited clinical development.\"},{\"question\":\"What direct and degradation-based approaches are highlighted for MYC inhibition?\",\"answer\":\"The text cites direct inhibition with Omomyc (OMO-103) and PROTAC-based degraders such as WBC100, emphasizing emerging clinical progress and feasibility.\"},{\"question\":\"How do combination therapies support MYC-targeted treatment?\",\"answer\":\"Combining MYC inhibitors with chemotherapy, radiotherapy, or immunotherapy is described as potentially synergistic, and the review emphasizes biomarker-guided rational combinations to improve outcomes and address resistance.\"}]","Rethinking MYC inhibition - a multi-dimensional approach to overcome cancer’s master regulator | PDF",1790161019,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a94ed46ad44bb3d6acea59d3a782219.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7add433bb4f873ff8f57885909f0483.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65eb85dcda8ff3607ffcda71ffa45f96.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0e8d481bfde49f356c15115b3ae8cfa.webp",980,1385]